CCR8在肿瘤免疫治疗中的研究进展

doi:10.19401/j.cnki.1007-3639.2024.03.008

摘要/Abstract

摘要：

目前针对肿瘤的治疗方法不断进步，免疫治疗已成为遏制肿瘤进展的有效手段。但目前的免疫治疗仍有局限性，只有较少的一部分特定患者可以从免疫治疗中完全获益。由于复杂的肿瘤微环境取决于不同的个体，所以免疫靶向药物在不同的肿瘤微环境中会受到不同程度的免疫抑制，从而无法发挥全部作用。在肿瘤微环境中，调节性T（regulatory T，Treg）细胞起到免疫抑制的作用，在许多瘤种中Treg细胞大量浸润从而造成肿瘤组织的免疫逃逸，会对治疗和预后产生不良影响。CC族趋化因子受体8（CC chemokine receptor 8，CCR8）属于CC族趋化因子受体家族，其主要在肿瘤微环境中的Treg细胞上特异性高表达，而在周围正常组织和外周血中低表达，因此CCR8可以作为Treg细胞的一种特异性标志物，是一种有潜力的治疗靶点和生物标志物。本文对近年来CCR8在不同瘤种中的研究进展进行了归纳和总结，以期为后续研究提供参考。

关键词: 肿瘤, CC族趋化因子受体8, 免疫治疗, 靶向治疗

Abstract:

Therapies for tumors continue to develop, and tumor immunotherapy has emerged as an effective means of controlling tumor progression. Given the limitations of immunotherapy, only some specific patients can benefit from immunotherapy. Since the complex tumor microenvironment is highly influenced by individual variability, immunotherapy will be subjected to different degrees of immune suppression in different tumor microenvironments and thus cannot exert its full effect. In the tumor microenvironment, regulatory T (Treg) cell plays as an immunosuppressive role. Numerous Treg cells infiltrate in indifferent tumor types, resulting in immune escape of tumor tissues, which will have a negative impact on treatment and prognosis. CC chemokine receptor 8 (CCR8) belongs to the CC chemokine receptor family. CCR8 is specifically expressed on Treg cell in the tumor microenvironment and expressed at low level in the surrounding normal tissues and peripheral blood thus it can be a specific marker for Treg cell. CCR8 is a potential therapeutic target and biomarker. This review summarized the research progress of CCR8 in different tumor types in recent years, so as to provide reference for subsequent research.

Key words: Tumor, CC chemokine receptor 8, Immunotherapy, Targeted therapy

中图分类号:

R730.51

陈亦凡, 李婷, 王碧芸. CCR8在肿瘤免疫治疗中的研究进展[J]. 中国癌症杂志, 2024, 34(3): 299-305.

CHEN Yifan, LI Ting, WANG Biyun. Research progress of CCR8 in tumor immunotherapy[J]. China Oncology, 2024, 34(3): 299-305.

参考文献 42

[1]	WEAVER J D, STACK E C, BUGGÉ J A, et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody[J]. Oncoimmunology, 2022, 11(1): 2141007.
[2]	VAN DAMME H, DOMBRECHT B, KISS M, et al. Therapeutic depletion of CCR8⁺ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy[J]. J Immunother Cancer, 2021, 9(2): e001749.
[3]	MOSER B. Chemokine receptor-targeted therapies: special case for CCR8[J]. Cancers, 2022, 14(3): 511.
[4]	MCCULLY M L, MOSER B. The human cutaneous chemokine system[J]. Front Immunol, 2011, 2: 33. doi: 10.3389/fimmu.2011.00033 pmid: 22566823
[5]	KARIN N. Chemokines and cancer: new immune checkpoints for cancer therapy[J]. Curr Opin Immunol, 2018, 51: 140-145. doi: S0952-7915(17)30141-3 pmid: 29579623
[6]	KUEHNEMUTH B, PISEDDU I, WIEDEMANN G M, et al. CCL1 is a major regulatory T cell attracting factor in human breast cancer[J]. BMC Cancer, 2018, 18(1): 1278.
[7]	LIU S S, LIU C, LV X X, et al. The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis[J]. Immunity, 2021, 54(10): 2433-2435. doi: 10.1016/j.immuni.2021.09.009
[8]	CHEN B W, ZHANG S Y, LI Q Y, et al. Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment[J]. Biosci Rep, 2020, 40(11): BSR20202042.
[9]	LOU X L, ZHAO K, XU J Z, et al. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: a bioinformatic analysis of the tumor microenvironment[J]. Front Immunol, 2022, 13: 950213. doi: 10.3389/fimmu.2022.950213
[10]	CHENIVESSE C, TSICOPOULOS A. CCL18 - beyond chemotaxis[J]. Cytokine, 2018, 109: 52-56. doi: S1043-4666(18)30034-6 pmid: 29402725
[11]	KORBECKI J, KOJDER K, SIMIŃSKA D, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4[J]. Int J Mol Sci, 2020, 21(21): 8412.
[12]	PLITAS G, RUDENSKY A Y. Regulatory T cells in cancer[J]. Annu Rev Cancer Biol, 2020, 4: 459-477. doi: 10.1146/cancerbio.2020.4.issue-1
[13]	WING J B, TANAKA A, SAKAGUCHI S. Human FOXP3⁺ regulatory T cell heterogeneity and function in autoimmunity and cancer[J]. Immunity, 2019, 50(2): 302-316. doi: 10.1016/j.immuni.2019.01.020
[14]	ANGELOVA M, CHAROENTONG P, HACKL H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy[J]. Genome Biol, 2015, 16(1): 64.
[15]	DE SIMONE M, ARRIGONI A, ROSSETTI G, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells[J]. Immunity, 2016, 45(5): 1135-1147. doi: S1074-7613(16)30432-0 pmid: 27851914
[16]	SUN F, ZHANG C, AI S C, et al. Identification of hub genes in gastric cancer by integrated bioinformatics analysis[J]. Transl Cancer Res, 2021, 10(6): 2831-2840. doi: 10.21037/tcr-20-3540 pmid: 35116593
[17]	WEI F Z, MEI S W, WANG Z J, et al. HAMP as a prognostic biomarker for colorectal cancer based on tumor microenvironment analysis[J]. Front Oncol, 2022, 12: 884474. doi: 10.3389/fonc.2022.884474
[18]	VILLARREAL D O, L’HUILLIER A, ARMINGTON S, et al. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer[J]. Cancer Res, 2018, 78(18): 5340-5348. doi: 10.1158/0008-5472.CAN-18-1119 pmid: 30026324
[19]	PLITAS G, KONOPACKI C, WU K M, et al. Regulatory T cells exhibit distinct features in human breast cancer[J]. Immunity, 2016, 45(5): 1122-1134. doi: S1074-7613(16)30443-5 pmid: 27851913
[20]	WANG L, SIMONS D L, LU X Y, et al. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer[J]. Nat Immunol, 2019, 20(9): 1220-1230. doi: 10.1038/s41590-019-0429-7
[21]	RUCKES T, SAUL D, VAN SNICK J, et al. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309[J]. Blood, 2001, 98(4): 1150-1159. doi: 10.1182/blood.v98.4.1150 pmid: 11493464
[22]	RONSLEY R, KARIMINIA A, NG B, et al. The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: results of the TACL T2009-008 phase I study[J]. Pediatr Hematol Oncol, 2019, 36(8): 468-481. doi: 10.1080/08880018.2019.1667461 pmid: 31530240
[23]	ZHENG D W, WANG X D, CHENG L, et al. The chemokine receptor CCR8 is a target of chimeric antigen T cells for treating T cell malignancies[J]. Front Immunol, 2022, 13: 808347. doi: 10.3389/fimmu.2022.808347
[24]	ERUSLANOV E, STOFFS T, KIM W J, et al. Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas[J]. Clin Cancer Res, 2013, 19(7): 1670-1680. doi: 10.1158/1078-0432.CCR-12-2091 pmid: 23363815
[25]	LIU X Q, XU X Y, DENG W, et al. CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells[J]. Mol Med Rep, 2019, 19(3): 1678-1686. doi: 10.3892/mmr.2018.9791 pmid: 30592282
[26]	WANG T, ZHOU Q, ZENG H, et al. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer[J]. Cancer Immunol Immunother, 2020, 69(9): 1855-1867. doi: 10.1007/s00262-020-02583-y pmid: 32367308
[27]	SUN Y X, ZHANG Q, YAO L L, et al. Comprehensive analysis reveals novel gene signature in head and neck squamous cell carcinoma: predicting is associated with poor prognosis in patients[J]. Transl Cancer Res, 2020, 9(10): 5882-5892. doi: 10.21037/tcr-20-805 pmid: 35117201
[28]	MENG L L, HE X X, HONG Q, et al. CCR4, CCR8, and P2RY14 as prognostic factors in head and neck squamous cell carcinoma are involved in the remodeling of the tumor microenvironment[J]. Front Oncol, 2021, 11: 618187. doi: 10.3389/fonc.2021.618187
[29]	FRAGA M, YÁÑEZ M, SHERMAN M, et al. Immunomodulation of T helper cells by tumor microenvironment in oral cancer is associated with CCR8 expression and rapid membrane vitamin D signaling pathway[J]. Front Immunol, 2021, 12: 643298. doi: 10.3389/fimmu.2021.643298
[30]	FUJIKAWA M, KOMA Y I, HOSONO M, et al. Chemokine (C-C motif) ligand 1 derived from tumor-associated macrophages contributes to esophageal squamous cell carcinoma progression via CCR8-mediated Akt/proline-rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway[J]. Am J Pathol, 2021, 191(4): 686-703. doi: 10.1016/j.ajpath.2021.01.004 pmid: 33460563
[31]	HARUNA M, UEYAMA A, YAMAMOTO Y, et al. The impact of CCR8⁺ regulatory T cells on cytotoxic T cell function in human lung cancer[J]. Sci Rep, 2022, 12(1): 5377.
[32]	DAS S, SARROU E, PODGRABINSKA S, et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses[J]. J Exp Med, 2013, 210(8): 1509-1528. doi: 10.1084/jem.20111627
[33]	BERENGUER J, LAGERWEIJ T, ZHAO X W, et al. Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8[J]. J Extracell Vesicles, 2018, 7(1): 1446660.
[34]	HUANG Y M, MOTTA E, NANVUMA C, et al. Microglia/macrophage-derived human CCL18 promotes glioma progression via CCR8-ACP5 axis analyzed in humanized slice model[J]. Cell Rep, 2022, 39(2): 110670.
[35]	GIUSTINIANI J, DOBOS G, MOINS-TEISSERENC H, et al. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas[J]. Blood Adv, 2022, 6(11): 3507-3512. doi: 10.1182/bloodadvances.2021006512 pmid: 35201316
[36]	CAMPBELL J R, MCDONALD B R, MESKO P B, et al. Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models[J]. Cancer Res, 2021, 81(11): 2983-2994. doi: 10.1158/0008-5472.CAN-20-3585
[37]	KIDANI Y, NOGAMI W, YASUMIZU Y, et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory[J]. Proc Natl Acad Sci U S A, 2022, 119(7): e2114282119.
[38]	WHITESIDE S K, GRANT F M, GYORI D S, et al. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function[J]. Immunology, 2021, 163(4): 512-520. doi: 10.1111/imm.13337 pmid: 33838058
[39]	LIU F T, WU H Y. CC chemokine receptors in lung adenocarcinoma: the inflammation-related prognostic biomarkers and immunotherapeutic targets[J]. J Inflamm Res, 2021, 14: 267-285. doi: 10.2147/JIR.S278395 pmid: 33574689
[40]	LI H L, WANG L H, HU Y L, et al. Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors[J]. World J Gastroenterol, 2020, 26(31): 4656-4668. doi: 10.3748/wjg.v26.i31.4656
[41]	CHEN G, CAI Z D, LIN Z Y, et al. ARNT-dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer[J]. Mol Carcinog, 2020, 59(8): 897-907. doi: 10.1002/mc.v59.8
[42]	YI G, GUO S W, LIU W Y, et al. Identification and functional analysis of heterogeneous FOXP3⁺ Treg cell subpopulations in human pancreatic ductal adenocarcinoma[J]. Sci Bull, 2018, 63(15): 972-981. doi: 10.1016/j.scib.2018.05.028